As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.
Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...